This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Fibroblast growth factor 13.
Plays a vital role in neuron polarization and migration in the cerebral cortex and the hippocampus. .
Human | |
---|---|
Gene Name: | FGF13 |
Uniprot: | Q92913 |
Entrez: | 2258 |
Belongs to: |
---|
heparin-binding growth factors family |
FGF13; FGF-13; FGF2Fibroblast growth factor homologous factor 2; FHF2FHF-2; fibroblast growth factor 13
Mass (kDA):
27.564 kDA
Human | |
---|---|
Location: | Xq26.3-q27.1 |
Sequence: | X; NC_000023.11 (138614727..139222889, complement) |
Ubiquitously expressed. Predominantly expressed in the nervous system.
Cell projection, filopodium. Cell projection, growth cone. Cell projection, dendrite. Nucleus. Cytoplasm. Not secreted.; [Isoform 1]: Nucleus, nucleolus.; [Isoform 2]: Cytoplasm. Nucleus.
You have probably heard of Boster Bio: Anti-Fibroblast Growth Factor 13 FGF13 Marker. This article will examine its use, availability, and cost. Read on to learn more. It's a popular product with applications in numerous fields, including rheumatoid arthritis, fibroblast growth, and other inflammatory diseases. But how do you use it? What are its limitations, however?
Boster Bio manufactures the anti-FGF13 marker. It is an approved genetic fragment. It is tested in IHC/WB using Human, Mouse and Rat tissues. It reacts well with other proteins found inside human tissues. It is therefore a good choice in research. For more information, please read on. The anti-FGF13 antibody is safe for routine research.
Fibroblast growth factors (FGF), a multifunctional protein, is a member of FGF homologous family (FHF). This family includes genes which regulate microtubules. These genes play important roles in the development and maintenance of the nervous systems. It is expressed in many tissues, including the brain and is associated with a wide range of diseases. The anti-FGF13 marker is a way to determine if your research was accurate and relevant.
The FGF13 protein is highly expressed in the spiral ganglion neurons and hair cells of the cochlea. Mice with FGF13 knockouts experience progressive hearing loss. These results provide hope for further research into FGF13’s function in otogenesis. The anti-FGF13 antibody also demonstrates high sensitivity for a wide range of applications, including cell biology and cancer.
Studies have shown FGF13 activates the AKT/GSK3 pathway. It also inhibits p21, p27 activity and enhances cells' transition from G1 phase to S phase. It also promotes cell proliferation. These findings suggest that FGF13 and SHCBP1 act cooperatively. However, it is difficult to prove that FGF13 causes cancer through the interaction of the two proteins.
We have created a FGF13-inducing heart-model by using ISO-treated NCMs. As measured by Phalloidin staining FGF13 levels increased and FGF13 transcription was higher than untreated NRCMSs. Interestingly, FGF13 expression was also associated with increases in transcription levels of hypertrophic and fibrotic marker genes.
While the role of FGF13 in brain development is not yet understood, it serves as a novel prognostic marker in patients with PCa following RP and improves the prediction of BCR-free survival. However, it is important in neuronal excitability. It is possible that wildervanck may be caused either by FGF13 mutants or Xchromosome deletions.
As a potential therapeutic target, FGF13 can be used to monitor the function of the NF-kB pathway in cardiomyocytes. It regulates NF-kB in cardiac myocytes, both under basal and stressful conditions. This protein may be targeted for the treatment of cardiac hypertrophy and heart disease. FGF13 must be first identified before you can implement a treatment for your heart failure.
A new study has revealed that FGF13 regulates NFB in cardiomyocytes. It interacts with the NLS of p65 and plays an important role in regulating NFKB activity. This study will open up new perspectives in studying FHFs in heart-related diseases. It will further demonstrate that FGF13 plays a significant regulatory role within the heart.
This study also suggests FGF13 regulates VGSC activity. FGF13 is also affected by a single mutation that inhibits FGF13's regulation of VGSCs. This suggests that the two proteins may act on each other in the brain in concerted actions. FGF13 cannot regulate the activity of VGSCs in central nervous system if it isn't expressed in the brain.
FGF13 receptor expression is high in the neuronal somatodendritic region of the mouse brain. Its homolog, FGF14 receptor, is more prevalent in the axon. The two proteins share similarities, including the FGF-like core domains and VGSC binding sites. Although they are likely to play different roles in the brains, this study will be vital for further research.
The resistance to platinum anticancer drugs is determined by the upregulation of FGF13 in HeLa cells. This marker seems to target molecules involved in maintaining low levels of intracellular platinum. It also helps to control intracellular levels of copper. This marker comes with a few costs. Here are some examples. These include: ($1,300).
Another potential mechanism to reduce the cost for the FGF13 marker is XLMR or X-linked multiplemerization. Duplication can interfere with a gene located at the boundary of a duplication region, which might lead to a dosage effect on the proteins encoded by the genes within. In a Borjeson-Forssmann-like patient, this breakpoint interrupts FGF13. Gecz et al. reported this. This was reported by Gecz et al. in 1999.
Boster Bio catalogs contain the FGF13 marker. This indicates the quality and purity of the antibody. This antibody reacts with human and mouse samples. It has been validated for use in WB and IHC. It is useful in pathology and cancer research. Here are some of the benefits of using this antigen. Continue reading to discover more. We will discuss both the benefits and the drawbacks of using them in the laboratory.
PMID: 8790420 by Smallwood P.M., et al. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development.
PMID: 10071193 by Gecz J., et al. Fibroblast growth factor homologous factor 2 (FHF2): gene structure, expression and mapping to the Borjeson-Forssman-Lehmann syndrome region in Xq26 delineated by a duplication breakpoint in a BFLS-like patient.